MEDTECH 2013 Conference Ensured That Bio/Med Technology Companies in New York Continue to Grow
Friday, October 11, 2013
MEDTECH 2013 focused on mapping the road to profitable growth for the bioscience and medical technology (bio/med) industry and ensured that the industry continues to grow in New York. One of the key ways that MedTech provides opportunities for bio/med companies to increase efficiency and continue to invest in life-saving medical technology is through the creation of the MedTech Purchasing Consortium. The MedTech Purchasing Consortium is a partnership in which leading product and service providers offer discounted pricing and special benefits on business expenses such as insurance, lab equipment, and office supplies. The costs of competing in the biotech industry can be burdensome to industry growth. By combining the purchasing power of its members, the MedTech Purchasing Consortium allows companies to do more at a lower cost – making business more efficient and productive.
“At MedTech we are constantly developing new ways to provide value to our members and grow the bio/med industry in New York. Our latest initiative, the MedTech Purchasing Consortium, will combine the power of our large and small business members to reduce operating costs, increase profitability, and invest in new cutting-edge patient centered medical devices. This is just one more tool for growth that MedTech provides for bio/med companies across New York State,” said MedTech President Jessica Crawford.
Additionally, MEDTECH 2013 demonstrated that MedTech continues to lead the fight in New York against the Affordable Care Act’s Medical Device Tax. The 2.3% excise tax on medical device sales is levied on companies regardless of profitability or size. The tax will significantly hinder medical device companies that want to bring products to market and solutions to patients. The tax could cost New York more than 1,700 jobs and a potential economic impact to the state totaling $357 million. “The Medical Device Tax has stripped tens of thousands of jobs and millions of research and development dollars away from medical device companies throughout New York and the United States pushing this valuable industry overseas. It is essential for the American economy and American patients that our government enables continued biomedical technology growth rather than suffocating it with a new tax - funds that could instead be devoted to providing good jobs for new college graduates. We have to fight to repeal the Medical Device Tax. This tax is sapping the lifeblood out the Nation's most innovative industry.” said MEDTECH 2013 Speaker, John Eckberg, The Cook Group’s Director, Media Relations.
MEDTECH 2013 also supported industry growth with the industry collaboration track “Reverse Pitch” session, START-UP NY guidance, a technology showcase, and an academic technology transfer with private industry panel.
Welch Allyn, Inc. participated in the industry collaboration track “Reverse Pitch” session. “Welch Allyn works with companies large and small to develop the innovative technology for medical professionals and patients. At MEDTECH 2013, we highlighted what we look for in partnerships with smaller life science companies. We know that through industry collaboration we will continue on a successful path and contribute to a robust bioscience and medical technology industry,” stated Sal Strods, Sr. Director, Diagnostic and Enabling Technologies at Welch Allyn, Inc.
As part of the “Opportunities for Growing Bio/Med Industry in NYS” panel, Ken Adams, President & CEO and Commissioner of New York State’s Empire State Development said, “New York State is committed to supporting innovative partnerships that connect businesses and academic institutions to promote job and industry growth by taking advantage of all of the resources that New York State has to offer. The bioscience and medical technology industry provides hundreds of thousands of direct and indirect jobs to New York State residents. At MEDTECH 2013, I highlighted how new initiatives like START-UP NY will further boost job creation throughout New York State.”
CONMED Corporation (CONMED) participated in the technology showcase. CONMED emphasizes surgical devices and equipment technology for minimally invasive procedures with revenues exceeding three-quarters of a billion dollars. As a global company, over 50% of revenues come from outside the United States. Approximately 80% of our medical devices are designed for one-time use by surgeons in a variety of specialties. As a founding member and loyal advocate of MedTech, we were happy to showcase our technology at MEDTECH 2013,” stated Daniel S. Jonas, Esq., Executive Vice President - Legal Affairs & General Counsel of CONMED.
As a panelist on the Collaborations between Academic Transfer Tech Offices and Private Industry forum, Alice Li, Cornell Center for Technology Enterprise & Commercialization (CCTEC) Director of Licensing/Ithaca Office stated, “Academic research programs offer a vast potential for economic growth throughout New York State. Marrying the interests between academic institutions and companies will cultivate a more successful biomedical technology industry in New York.”
MEDTECH 2013 concluded with the announcement of new MedTech Board members including:
• Kimberly Briggs, Vice President Regulatory Affairs, Vision Care and Surgical Products at Valeant Pharmaceuticals (Bausch & Lomb Division), Rochester, NY
• Joseph DeVivo, President and CEO AngioDynamics, Latham, NY
• Richard M. Eglen, Ph.D., Vice President and General Manager, Corning Inc., Life Sciences, Tewksbury, MA
• James Gabalski, VP - Marketing, North America, Getinge Infection Control, Rochester, NY
• Holly Hillberg, Vice President, Research & Development Worldwide, Ortho Clinical Diagnostics, Rochester, NY
• Daniel Jonas, Vice President Legal Affairs and General Counsel, CONMED Corporation, Utica, NY
• Tracy MacNeal, Chief Strategy Officer, ATW Companies, Inc., Warwick RI
• William Maggio, President and CEO, IMMCO Diagnostics, Buffalo NY
• Harold Meckler, President and CSO, Chemapotheca, Delmar NY
• Max Kunz, Chief Executive Officer, Volpi Manufacturing USA, Auburn, NY
• Gerry Murak, Chief Executive Officer, SoPark Corporation, Buffalo, NY
• Amy Ryan, former Director of Operations, Varian Medical Systems, X-Ray Products, Liverpool, NY
• John Boger, Partner, Heslin Rothenberg Farley & Mesiti P.C., Albany, NY
• Jack Rudnick, Director of the Technology Commercialization Law Program, Syracuse University Law School, Syracuse, NY
• Scott Steele, Director of Research Alliances, University of Rochester, Rochester, NY
MedTech thanks all of its MEDTECH 2013 sponsors including Platinum Sponsors CONMED Corporation, Ortho Clinical Diagnostics, and Welch Allyn.
MedTech is a bioscience and medical technology industry association in New York State. MedTech is celebrating its 10th anniversary this year marking a decade of connecting New York State's bioscience and medical technology industry. MedTech has nearly 100 members throughout New York including sustaining members AngioDynamics (Latham, NY), CONMED Corporation (Utica, NY), Corning (Corning, NY), Ortho Clinical Diagnostics of Johnson & Johnson (Rochester, NY), and Welch Allyn (Skaneateles, NY).